“Towards eliminating viral hepatitis”: Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination KariLancaster, TimRhodes, JakeRance International Journal of Drug Policy, Volume 80, June 2020, 102419, d…

Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Versfeld, A., McBride, A., Scheibe, A. et al.  Harm Reduct J 17, 39 (2020). doi.org/10.1186/s12954-020-00382-…

Hepatitis B Virus DNA is a Substrate for the cGAS/STING Pathway but is not Sensed in Infected Hepatocytes. Lauterbach-Rivière, L.; Bergez, M.; Mönch, S.; Qu, B.; Riess, M.; Vondran, F.W.R.; Liese, J.; Hornung, V.; Urban, S.; König, R.  Viruse…

Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada  Broad J, Mason K, Guyton M, Lettner B, Matelski J, Powis J.  [published online ahead of print, 2020 May 13]. Int J Drug P…

Prisoners should not be left behind in HCV research and policies.  Moazen, B., Stöver, H., Dolan, K. et al.  Harm Reduct J 17, 33 (2020). doi.org/10.1186/s12954-020-00379-y https://harmreductionjournal.biomedcentral.com/a…

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. Hinrichsen H, Stoehr…